NASDAQ:ANGO

AngioDynamics Stock Forecast, Price & News

$25.31
-1.66 (-6.15 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.04
$27.11
50-Day Range
$24.76
$29.20
52-Week Range
$9.36
$30.25
Volume796,355 shs
Average Volume273,644 shs
Market Capitalization$973.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83
30 days | 90 days | 365 days | Advanced Chart
Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.


AngioDynamics logo

About AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

555th out of 1,349 stocks

Surgical & Medical Instruments Industry

57th out of 123 stocks

Analyst Opinion: 2.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

Is AngioDynamics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics
or view top-rated stocks.

What stocks does MarketBeat like better than AngioDynamics?

Wall Street analysts have given AngioDynamics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AngioDynamics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Thursday, September 30th 2021.
View our earnings forecast for AngioDynamics
.

How can I listen to AngioDynamics' earnings call?

AngioDynamics will be holding an earnings conference call on Thursday, September 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13723182".

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings data on Monday, March, 29th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.04. The medical instruments supplier earned $71.18 million during the quarter, compared to analyst estimates of $68.42 million. AngioDynamics had a negative net margin of 10.84% and a positive trailing twelve-month return on equity of 0.41%.
View AngioDynamics' earnings history
.

How has AngioDynamics' stock been impacted by Coronavirus (COVID-19)?

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANGO stock has increased by 149.6% and is now trading at $25.31.
View which stocks have been most impacted by COVID-19
.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY 2022 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.070. The company issued revenue guidance of $305 million-$310 million, compared to the consensus revenue estimate of $297.90 million.

What price target have analysts set for ANGO?

3 brokers have issued 1 year price targets for AngioDynamics' shares. Their forecasts range from $28.00 to $32.00. On average, they anticipate AngioDynamics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts' price targets for AngioDynamics
or view top-rated stocks among Wall Street analysts.

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the following people:
  • James Christopher Clemmer, President, Chief Executive Officer & Director
  • David D. Helsel, SVP-Global Operations, Research & Development (LinkedIn Profile)
  • Stephen A. Trowbridge, Chief Financial Officer & Executive Vice President
  • Kim L. Seabury, Senior Vice President-Information Technology
  • Juan Carlos Serna, Senior VP-Scientific & Clinical Affairs

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AngioDynamics' key competitors?

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.59%), Dimensional Fund Advisors LP (7.37%), Vanguard Group Inc. (6.57%), Victory Capital Management Inc. (6.10%), FMR LLC (5.41%) and State Street Corp (4.90%). Company insiders that own AngioDynamics stock include Dave Helsel, James C Clemmer, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics
.

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., State Street Corp, Prudential Financial Inc., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Bank of America Corp DE, Renaissance Technologies LLC, and Nuveen Asset Management LLC. Company insiders that have sold AngioDynamics company stock in the last year include Dave Helsel, and Wesley Johnson.
View insider buying and selling activity for AngioDynamics
or view top insider-selling stocks.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Frontier Capital Management Co. LLC, FMR LLC, EAM Investors LLC, JPMorgan Chase & Co., Morgan Stanley, and Morgan Stanley. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
or or view top insider-buying stocks.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $25.31.

How much money does AngioDynamics make?

AngioDynamics has a market capitalization of $973.02 million and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31,550,000.00 in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does AngioDynamics have?

AngioDynamics employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.

When was AngioDynamics founded?

AngioDynamics was founded in 1988.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

Where are AngioDynamics' headquarters?

AngioDynamics is headquartered at 14 PLAZA DRIVE, LATHAM NY, 12110.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at (518) 795-1400 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.